Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UVYLY
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
sYS6005
|
|||||
| Synonyms |
SYS6005; SYS6005Y; SYSY2107; RB-164
Click to Show/Hide
|
|||||
| Organization |
CSPC Pharmaceutical Group (Originator);Radiance
|
|||||
| Drug Status |
Phase 1
|
|||||
|
|
||||||
| Antibody Name |
Anti-ROR1 Fc-silenced mAb
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Enzymatic Catalysis
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific non-hodgkin lymphoma |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|